文献速递糖尿病

比利时1型糖尿病成人中Dexcom G6实时持续葡萄糖监测与FreeStyle Libre 1间歇扫描式持续葡萄糖监测的成本-效用分析

Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium.
PubMed 文献 · Diabetologia · 2024-01-18

研究基于ALERTT1随机试验数据,用IQVIA CORE糖尿病模型评估比利时1型糖尿病成人中Dexcom G6实时持续葡萄糖监测(rtCGM)对比FreeStyle Libre 1间歇扫描式持续葡萄糖监测(isCGM)的长期成本-效用。基础病例中两者定价均为3.92欧元/天(不含增值税),rtCGM在终身时间 horizon 内占优,产生更低的糖尿病相关并发症成本和更好的健康结局。当rtCGM价格为5.11欧元/天(涨价30.4%)或12.34欧元/天(涨价214.8%)时,分别达到成本中性或增量成本-效用比为每质量调整生命年40,000欧元。

要点

  • 基础病例中rtCGM占优isCGM,糖尿病相关并发症成本更低且健康结局更好。
  • rtCGM价格升至5.11欧元/天(涨30.4%)时成本中性,升至12.34欧元/天(涨214.8%)时ICER为每QALY 40,000欧元。
  • rtCGM优势的主要驱动因素为更低的HbA1c、更少的严重低血糖事件和减少的低血糖恐惧。

核心结论

  • 当定价相似时,Dexcom G6 rtCGM(带警报功能)对比FreeStyle Libre 1 isCGM(无警报)在比利时1型糖尿病成人中具有经济和临床获益,似乎是一种成本-有效的葡萄糖监测方式。

研究设计与样本

  • 使用IQVIA CORE糖尿病模型进行成本-效用分析,模拟基线队列数据来源于随机ALERTT1试验(ClinicalTrials.gov NCT03772600)。
  • 参与者年龄42.9±14.1岁(均值±标准差),基线HbA1c为57.8±9.5 mmol/mol(7.4±0.9%)。
  • 分析从比利时医疗支付方视角进行,采用终身时间 horizon,健康结局以质量调整生命年表示。
  • 基础病例中rtCGM和isCGM均按比利时报销系统定价为3.92欧元/天(不含增值税)。
  • 使用概率和单因素敏感性分析处理参数不确定性。

主要发现

  • 基础病例中rtCGM占优isCGM,导致更低的糖尿病相关并发症成本和更好的健康结局。
  • rtCGM使用者的HbA1c降低3.6 mmol/mol(0.36个百分点),基于6个月组间平均差异。
  • 支持rtCGM的主要驱动因素为更低的HbA1c、更少的严重低血糖事件和减少的低血糖恐惧。
  • 结果在广泛单因素敏感性分析下稳健。
  • 在rtCGM价格为5.11欧元/天(涨价30.4%)的模型中rtCGM成本中性,在12.34欧元/天(涨价214.8%)时增量成本-效用比为每质量调整生命年40,000欧元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to assess the long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring (rtCGM) with alert functionality compared with FreeStyle Libre 1 intermittently scanned continuous glucose monitoring (isCGM) without alerts in adults with type 1 diabetes in Belgium. METHODS: The IQVIA CORE Diabetes Model was used to estimate cost-effectiveness. Input data for the simulated baseline cohort were sourced from the randomised ALERTT1 trial (ClinicalTrials.gov. REGISTRATION NO: NCT03772600). The age of the participants was 42.9 ± 14.1 years (mean ± SD), and the baseline HbA1c was 57.8 ± 9.5 mmol/mol (7.4 ± 0.9%). Participants using rtCGM showed a reduction in HbA1c of 3.6 mmol/mol (0.36 percentage points) based on the 6-month mean between-group difference. In the base case, both rtCGM and isCGM were priced at €3.92/day (excluding value-added tax [VAT]) according to the Belgian reimbursement system. The analysis was performed from a Belgian healthcare payer perspective over a lifetime time horizon. Health outcomes were expressed as quality-adjusted life years. Probabilistic and one-way sensitivity analyses were used to account for parameter uncertainty. RESULTS: In the base case, rtCGM dominated isCGM, resulting in lower diabetes-related complication costs and better health outcomes. The associated main drivers favouring rtCGM were lower HbA1c, fewer severe hypoglycaemic events and reduced fear of hypoglycaemia. The results were robust under a wide range of one-way sensitivity analyses. In models where the price of rtCGM is €5.11/day (a price increase of 30.4%) or €12.34/day (a price increase of 214.8%), rtCGM was cost-neutral or reached an incremental cost-effectiveness ratio of €40,000 per quality-adjusted life year, respectively. CONCLUSIONS/INTERPRETATION: When priced similarly, Dexcom G6 rtCGM with alert functionality has both economic and clinical benefits compared with FreeStyle Libre 1 isCGM without alerts in adults with type 1 diabetes in Belgium, and appears to be a cost-effective glucose monitoring modality. Trial registration ClinicalTrials.gov NCT03772600.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Visser MM, Van Muylder A, Charleer S, et al. Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium. Diabetologia. 2024. PMID: 38236409. doi:10.1007/s00125-023-06084-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。